Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rational immunotherapy with interleukin 2.

G Kaplan1, Z A Cohn, K A Smith

  • 1Laboratory of Cellular Physiology & Immunology, Rockefeller University, New York, NY 10021.

Bio/Technology (Nature Publishing Company)
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum YKL-40 level is correlated with apnea hypopnea index in patients with obstructive sleep apnea sindrome.

European review for medical and pharmacological sciences·2017
Same author

Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199].

Journal of hepatology·2017
Same author

RETRACTED: Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease.

Journal of hepatology·2016
Same author

The use of short message services (SMS) to provide medical updating to parents in the NICU.

Journal of perinatology : official journal of the California Perinatal Association·2016
Same author

The joint association of self-rated health and diabetes status on 14-year mortality in elderly men and women.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2016
Same author

Socio-economic patterning in adulthood and depressive symptoms among a community sample of older adults in the United States.

Public health·2015
Same journal

Molecular Farming: Transgenic Animals as Bioreactors.

Bio/technology (Nature Publishing Company)·2020
Same journal

Development of a Genetically-Engineered, Candidate Polio Vaccine Employing the Self-Assembling Properties of the Tobacco Mosaic Virus Coat Protein.

Bio/technology (Nature Publishing Company)·2020
Same journal

FDA User Fees Gain Momentum.

Bio/technology (Nature Publishing Company)·2020
Same journal

Cloning of a Gene Involved in Antibiotic Synthesis.

Bio/technology (Nature Publishing Company)·2020
Same journal

The Biology of the Interferon System.

Bio/technology (Nature Publishing Company)·2020
Same journal

Development of new cloning vectors for the production of immunogenic outer membrane fusion proteins in Escherichia coli.

Bio/technology (Nature Publishing Company)·1996
See all related articles

Interleukin 2 (IL-2) shows promise for treating infectious diseases like leprosy and AIDS by boosting cell-mediated immunity. Low doses of IL-2 effectively stimulate immune response without causing systemic toxicity in patients.

Area of Science:

  • Immunology
  • Oncology
  • Infectious Diseases

Background:

  • Interleukin 2 (IL-2) is a T lymphocyte cytokine.
  • IL-2 has been utilized in high-dose cancer therapy for over five years.
  • IL-2's role in stimulating cell-mediated immunity for infectious diseases is increasingly recognized.

Purpose of the Study:

  • To review the use of Interleukin 2 (IL-2) in treating lepromatous leprosy and AIDS.
  • To focus on low, physiologic doses of IL-2.
  • To evaluate IL-2's efficacy in stimulating cell-mediated immunity.

Main Methods:

  • Review of existing data on IL-2 structure, cellular, and molecular effects.
  • Analysis of IL-2's application in patients with lepromatous leprosy and AIDS.
  • Assessment of immune response and systemic toxicity at low IL-2 doses.

Related Experiment Videos

Main Results:

  • IL-2 effectively stimulates cell-mediated immunity.
  • Low-dose IL-2 administration in patients with lepromatous leprosy and AIDS demonstrated positive immune modulation.
  • No significant systemic toxicity was observed with low-dose IL-2 therapy.

Conclusions:

  • Physiologic doses of IL-2 are effective in stimulating cell-mediated immunity.
  • IL-2 represents a potential therapeutic agent for infectious diseases like lepromatous leprosy and AIDS.
  • Low-dose IL-2 therapy offers a safe approach to enhancing immune response in specific patient populations.